Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lennox Gastaut Syndrome: full-pipeline trial registry
3 of 11 indexed Lennox Gastaut Syndrome trials are currently recruiting.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 3 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Lennox Gastaut Syndrome: 11 US clinical trials tracked, 3 recruiting.
Lennox Gastaut Syndrome is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Longboard Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition lennox-gastaut-syndrome
OPEN 3 | RECR 27% | LATE 5 | EARLY 5 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Atherosclerotic Cardiovascular Disease (27% recruiting · 22 trials)
Lennox Gastaut Syndrome lists 3 open slots (27% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lennox Gastaut Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lennox Gastaut Syndrome is recruiting below its size-band peers.
3 of 11 indexed trials (27.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lennox Gastaut Syndrome research.
Longboard Pharmaceuticals accounts for 2 of 11 trials (18.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Lennox Gastaut Syndrome enrolment sits around 154 participants.
Median target enrolment is 154 among the 11 trials that report a genuine target (sentinel values excluded). 5 of those (45.5%) plan for fewer than 100 participants.
-
Lennox Gastaut Syndrome research is mostly interventional.
10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome
Ann & Robert H Lurie Children's Hospital of Chicago
NCT05374824
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
Epygenix
NCT05066217
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
SK Life Science
NCT05219617
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Jazz Pharmaceuticals
NCT05044819
RNS System LGS Feasibility Study
NeuroPace
NCT05339126
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
Zogenix
NCT03936777
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
Jazz Pharmaceuticals
NCT02224690
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
Longboard Pharmaceuticals
NCT05364021
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
NCT05626634
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
SK Life Science
NCT04062981
A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol
Zogenix International Limited, Inc., a subsidiary of Zogenix
NCT03467113
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lennox Gastaut Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lennox Gastaut Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lennox Gastaut Syndrome page
11 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Lennox Gastaut Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Longboard Pharmaceuticals sponsors the most Lennox Gastaut Syndrome trials on record, review their full trial history before evaluating a specific study. See Longboard Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lennox Gastaut Syndrome condition card totals 11 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.